key: cord-0763011-c7b68bb7
authors: Hoffman, Robert L.; Kania, Robert S.; Brothers, Mary A.; Davies, Jay F.; Ferre, Rose A.; Gajiwala, Ketan S.; He, Mingying; Hogan, Robert J.; Kozminski, Kirk; Li, Lilian Y.; Lockner, Jonathan W.; Lou, Jihong; Marra, Michelle T.; Mitchell, Lennert J.; Murray, Brion W.; Nieman, James A.; Noell, Stephen; Planken, Simon P.; Rowe, Thomas; Ryan, Kevin; Smith, George J.; Solowiej, James E.; Steppan, Claire M.; Taggart, Barbara
title: Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
date: 2020-10-15
journal: J Med Chem
DOI: 10.1021/acs.jmedchem.0c01063
sha: 9dcc6653f81d9a63e6359106849358e52d2440a4
doc_id: 763011
cord_uid: c7b68bb7

[Image: see text] The novel coronavirus disease COVID-19 that emerged in 2019 is caused by the virus SARS CoV-2 and named for its close genetic similarity to SARS CoV-1 that caused severe acute respiratory syndrome (SARS) in 2002. Both SARS coronavirus genomes encode two overlapping large polyproteins, which are cleaved at specific sites by a 3C-like cysteine protease (3CL(pro)) in a post-translational processing step that is critical for coronavirus replication. The 3CL(pro) sequences for CoV-1 and CoV-2 viruses are 100% identical in the catalytic domain that carries out protein cleavage. A research effort that focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CL(pro) employing ligand-protease structures solved by X-ray crystallography led to the identification of 3 and 4. Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CL(pro) with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.

In late 2019, cases of an unknown respiratory tract infection were first reported in Wuhan, China. By February 2020, the novel coronavirus SARS CoV-2 was identified as the causative agent for COVID-19. 1,2 Genome analysis of this virus revealed a high similarity to SARS CoV-1, the coronavirus that caused severe acute respiratory syndrome (SARS) in 2002−2003. 2−4 Like SARS CoV-1, which resulted in 799 deaths among the 8464 probable cases, 5 SARS CoV-2 can induce fever, coughing, and difficulty breathing that rapidly becomes more serious in some cases. The spread of SARS CoV-2 has been more extensive than that of SARS CoV-1, causing a global pandemic with the current number of worldwide infections surpassing eight million and deaths surpassing 400,000. 6 The SARS CoV-1 genome encodes for two large polyproteins pp1a (∼450 kDa) and pp1ab (∼750 kDa) that contain overlapping sequences and include a 3C-like cysteine protease (3CL pro ). The function of this internally encoded 3CL pro is integral to the processing of these proteins and critical for viral replication. 7 The SARS CoV-1 3CL pro shares a high degree of structural homology and similar substrate specificity with the coronavirus 3C-like cysteine proteases of hCoV 229E and TGEV 8 but is most similar to the SARS CoV-2 3CL pro . Specifically, the SARS CoV-1 and SARS CoV-2 share 96% identity between their respective 3CL pro sequences and 100% identity in the active site. 8 A recent report by Dai et al. demonstrates that crystallographic information and structure− activity relationships obtained with the SARS CoV-1 3CL pro could facilitate the design of potent SARS CoV-2 3CL pro inhibitors with antiviral potency. 9 There are numerous reports of reversible cysteine protease inhibitors, which include aldehydes, 10−13 thio-or oxymethylketones, 14 cyclic ketones, 15 amidomethylketones, 16 nitriles, 17, 18 or various 1,2-dicarbonyl motifs. 19, 20 The electrophilic carbon of these chemotypes reacts reversibly with the sulfur atom of an active-site cysteine forming a covalently bound tetrahedral complex. Stabilization of this charged protein−ligand transition state by an "oxyanion hole" present in the active site has been observed with certain inhibitor classes by X-ray crystallography and NMR. 21, 22 A recent report describes the optimization of a series of peptidomimetics designed with an α-ketoamide warhead, which achieves broadspectrum inhibition against the M pro for several coronaviruses and enteroviruses. Importantly, the reported protease potencies correlate to antiviral potencies, and the authors suggest that the reported SARS CoV-1 3CL pro activity of their lead could be predictive of the SARS CoV-2 3CL pro activity. 23 Alternative modes of enzyme inhibition are covalently bound irreversible inhibitors. While chemically reactive affinity labels such as chloromethylketones (CMKs) have demonstrated potent protease inhibition and in certain instances in vivo activity, their inherent chemical reactivity precludes development as clinical agents due to safety concerns. 24 However, acyloxymethylketones first reported by Krantz as "quiescent affinity labels" for cathepsin B have demonstrated potent levels of enzyme inhibition with relatively low chemical reactivity. 25, 26 Mechanistic studies of this class of inhibitors with the cysteine protease caspase-1 support the intermediacy of a thiohemiketal arising from the initial 1,2-carbonyl attack. Orientation and stabilization of the acyloxy leaving group within the S 1 ′ domain (Figure 1 ) of the protease can facilitate S N 2 displacement via sulfur migration, resulting in irreversible or bimodal (reversible inhibition followed by slow inactivation) inhibition. 27 Following the SARS outbreak, a CoV-1 3CL pro homology model was published in 2003 with comparisons made to the human rhinovirus (HRV) 3C pro . 28 Although these two proteases share very little sequence conservation, the substrate consensus sequences have a Gln residue in common at P 1 . Analysis of the HRV 3C pro crystal structure with 1 (rupintrivir; Figure 2 ) revealed binding interactions that are like those observed for 1 bound to TGEV 3CL pro , which was used in the construction of their homology model. The authors concluded that Michael acceptor 1 would serve as a starting point to expedite the identification of a potent SARS CoV-1 3CL pro inhibitor.

Performing a similar analysis, we tested 1 and additional HRV 3C pro inhibitors that displayed very weak to unmeasurable SARS CoV-1 3CL pro inhibition. Concurrently, new Michael acceptor derivatives were designed that tested P 1 /P 2 alterations and truncation of the P 3 /P 4 binding motif to optimize SARS CoV-1 3CL pro inhibition. Compound 2, a derivative that contains an indole capping group at P 2 , displayed modest levels of irreversible inhibition (k obs /I = 586 ± 11 M −1 s −1 ) that enabled cocrystallization in complex with SARS CoV-1 3CL pro (PDB code 6XHO). 29 Comparison of this structure with the complex of 1 in HRV 3C pro helped to rationalize the poor performance of the warhead, which had been successful in HRV. The structure of the SARS CoV-1 3CL pro complex revealed an eclipsed torsion about the resulting sp 3 α,β-carbons from the Michael acceptor ( Figure  3 ). Furthermore, the carbonyl oxygen sp 2 lone pair electrons are not aligned well with either 3CL pro hydrogen bond donor of the oxyanion hole. Specifically, the hydrogen bond between the carbonyl oxygen and the Gly143 NH in the SARS CoV-1 3CL pro complex is 3.4 Å, while the corresponding hydrogen bond distance is a much more favorable 2.8 Å in the complex of 1 with HRV 3C pro . In contrast to these unfavorable interactions, the constrained lactam 30 at the P 1 site, which was designed to be isosteric with the highly conserved P 1 glutamine present in all SARS CoV substrates, is well positioned in the S 1 pocket making a favorable hydrogen bond to His163. The NH of the lactam is within the hydrogen bond distance to Glu166 and the backbone oxygen of Phe140 in the 3CL pro . Additionally, the NH of the indole P 2 capping moiety makes a hydrogen bond with the protein backbone while it extends across an otherwise lipophilic surface over the P 3 pocket.

Although the structure of 2 in complex with SARS CoV-1 3CL pro is the final product, the above analysis is expected to apply similarly to the more relevant and structurally close transition state. Accordingly, a focused design strategy aimed at replacing the warhead while retaining the P 1 lactam and utilizing the methoxy indole capping group in the early rounds of optimization was initiated. Specifically, an ideal electrophilic warhead would be bioisosteric, with the scissile amide carbonyl of peptidyl substrates ensuring proper alignment within the oxyanion hole of the protease. To better mimic the tetrahedral intermediate generated in the amide bond cleavage, we designed ketone-based covalent reversible and irreversible inhibitors of SARS CoV-1 3CL pro , as illustrated by 3 and 4. Compound 4 was selected as a development candidate for SARS CoV-1 but with the successful public health response that ended the 2003 pandemic, the clinical advancement of 4 was suspended. Following the COVID-19 outbreak, testing has demonstrated that 4 is a potent inhibitor of the SARS CoV-2 3CL pro (K i = 0.27 ± 0.1 nM) and a cocrystal structure with 4 bound in the active site has been solved. In addition to the potent inhibition of the 3CL pro and viral replication of several coronaviruses, 4 possesses solubility as well as metabolic and chemical stability characteristics, which are consistent with a continuous infusion IV therapeutic treatment for COVID-19. We report the research focused on the discovery of reversible and irreversible ketone-based inhibitors of SARS CoV-1 3CL pro employing ligand-protease structures solved by X-ray crystallography, which led to the identification of 4 as a molecule Amino acid residues to the left of the polypeptide scissile amide bond are numbered sequentially, beginning with P 1 and increasing toward the N-terminus. Amino acid residues to the right of the scissile bond are numbered sequentially, beginning with P 1 ′ and increasing toward the C-terminus. Complimentary regions of the protease active site employ the corresponding S numbering. warranting further evaluation for its potential to treat coronaviruses, including COVID-19.

Chemistry. Central to our strategy of examining ketonebased thiophiles was the preparation of an array of intermediates containing diverse methylketone moieties and protecting groups. The preparation of halomethylketone intermediates was accomplished in a two-step procedure by the generation of a diazoketone intermediate 31 or directly by a modified Kowalski−Haque reaction, 32 as depicted in Scheme 1.

Saponification of amino ester 5 33 afforded the corresponding amino acid 6 in nearly quantitative yield. Acid 6 was treated with isobutylchloroformate and triethylamine, and the resulting mixed anhydride was reacted with diazomethane 34 to provide high isolated yields of 7. Diazoketone 7 was treated with hydrochloric acid for simultaneous nitrogen deprotection and conversion to the chloromethylketone (CMK) intermediate 10. Alternatively, the N-Boc-protected bromomethylketone was prepared by treatment of 7 with stoichiometric Scheme 1. Preparation of P 1 Synthetic Intermediates a (i) 3 M NaOH, MeOH (95%), (ii) isobutylchloroformate (IBCF), triethylamine (TEA), tetrahydrofuran (THF), (iii) CH 2 N 2 /ether (92%), (iv) 4 M HCl/dioxane (83%), (v) 1.0 equiv 48% HBr (83%), (vi) HNCH 3 (OCH 3 ), EDC, HOBt, NMM, dichloromethane (DCM) (79%), (vii) Mg, HgCl 2 , BOM-Cl, THF, −78°C (50%), and (viii) lithium diisopropylamide (LDA), ClCH 2 I, THF (54%).

a quantities of 48% HBr in dichloromethane to provide 11. Another preparation of CMK intermediates that avoids the use of diazomethane was accomplished by the reaction of 5 with excess LDA and chloroiodomethane to afford 8 in moderate yields. A direct approach to oxymethylketone intermediate 9 was achieved by conversion of acid 6 to the corresponding Weinreb amide followed by treatment with the Grignard generated from benzyl chloromethyl ether. 35 A key element for rapid access to substituted methylketone derivatives was the generation of the fully elaborated CMK 12 (Scheme 2). The utility of the CMK moiety to prepare acyloxy-and hydroxy-substituted methylketones is well established. Elaboration of 10 in a sequence of deprotection/ 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU)-mediated peptide couplings provided CMK derivative 12 in moderate yield with no epimerization observed. Reaction of 12 with various carboxylic acids in the presence of cesium fluoride at 60°C provided acyloxymethylketones 13−28. Using this synthetic approach with substitution of P 2 and amine capping structural elements provided inhibitors 3 and 29−31.

Hydroxymethylketone (HMK) derivatives were accessed by two complimentary approaches illustrated in Scheme 3. Elaboration of the P 1 ′-protected oxygen intermediate 9 by sequential amide bond coupling reactions provided benzylether derivatives such as 34 in moderate yields with a low propensity for epimerization at the P 1 center. Hydrogenolytic debenzylation readily afforded the final HMK inhibitors exemplified by 36. Alternatively, fully elaborated CMK derivatives such as 35 were reacted with benzoylformic acid followed by methanolysis to generate HMK final products such as 36. 36 Alkylation of the terminal hydroxyl was achieved under microwave-assisted conditions in the presence of silver (I) oxide to afford alkoxymethylketone inhibitors, as illustrated by 37. Using these two synthetic approaches with substitution of P 2 and amine capping structural elements provided inhibitors 4 and 38−50.

Biological Evaluation. Irreversible Inhibitors of SARS CoV-1 3CL pro . The warhead reactivity and binding affinity to P 1 ′ are both important design considerations to ensure specificity of irreversible inhibitors. Krantz has demonstrated that the inherent chemical reactivity of acyloxymethylketones can be tuned to inhibit cysteine proteases through the modulation of substituent effects on the carboxylate leaving group. 37 The importance of leaving group "strength" was confirmed by the strong dependence between the pK a of the leaving carboxylate and cathepsin B enzyme inhibition. These otherwise weak electrophiles are elegant "quiescent" inhibitors that harness the very same interactions with catalytic residues that lead to proteolysis rate acceleration. Molecular modeling of a 2,6-dichlorobenzoate design with SARS CoV-1 3CL pro indicated that a low strain conformation of the ketone carbonyl was aligned in the oxyanion hole and the substituted benzoate is accommodated within the P 1 ′ site. A series of acyloxymethylketone derivatives were prepared, as depicted in Table  1 .

As expected, chloromethylketone 12 is a potent irreversible inhibitor of SARS CoV-1 3CL pro . Compounds 22−25 possess the most electron-deficient benzoate leaving groups and display kinetics consistent with irreversible inhibition. The remaining entries appear to be reversible inhibitors in the time scale of the assay, with 28 possessing the most potent IC 50 . A 38 of 28 in complex with SARS CoV-1 3CL pro at 2.25 Å shows a covalent adduct, which demonstrates the bimodal activity of certain acyloxy inhibitors ( Figure 4 ). In this structure, the electron density for the 2cyanobenzoate moiety is absent and the 3CL pro active-site cysteine (Cys145) sulfur forms a covalent bond to the methylene carbon (1.8 Å C−S bond length). The ketone carbonyl is positioned within the oxyanion hole and as such engaging in hydrogen bonds with backbone NH groups of Gly143 and Cys145. A detailed analysis of an extended hydrogen bond network from catalytic His41 reveals that the side-chain imidazole serves as a hydrogen bond donor to the interior of the protease. Specifically, the imidazole hydrogen is directed toward a lone pair electron acceptor from a structural water. We can conclude that this water must be an acceptor to His41 as one of the water hydrogens is engaged with acceptor electrons on the side chain of Asp187, and the second hydrogen engages a terminating acceptor backbone carbonyl on Asp176 through a short network that includes the side chains of an internal, neutral His164 and Thr175. The 2,6-dichlorobenzoate derivative 22 displays the highest levels of potency in the SARS CoV-1 3CL pro and in antiviral cytopathic effect assays in Vero 76 cells (EC 50 = 0.29 ± 0.19 μM). 39 We note here that the assay in Vero 76 cells provided data establishing antiviral activity, but the translation of potency measured in Vero cells, which have high efflux potential, to the potency achievable in human lung cells was unknown (vide infra). As expected, 22 possesses low levels of reactivity toward endogenous nucleophiles such as glutathione (t 1/2 > 60 min) 40 and exhibits high levels of stability in human plasma (t 1/2 > 240 min). 41 Although 22 displays a promising activity profile, it possesses very poor solubility in clinically relevant IV vehicle formulations, thus limiting its development as an IV clinical agent.

To improve the solubility characteristics of inhibitors incorporating the lipophilic 2,6-dichlorobenzoate, a limited set of inhibitors containing smaller or more polar amine capping fragments were prepared ( Table 2) . Replacement of the 4-methoxy indole cap present in 22 with a benzimidazole provided 31. This inhibitor displayed potent irreversible inhibition kinetics but did not improve solubility compared to 22. Reduction in the size of the P 2 capping element as represented by 29 and 30 provided derivatives that possessed weak reversible SARS CoV-1 3CL pro inhibition.

Another design to replace the 4-methoxy indole was the (2R)-tetrahydrofuran-2-carboxylate, which molecular modeling suggested could make additional favorable protein interactions with a Gln189 side chain and led to the preparation of 3. Initially, this derivative appeared to display reversible binding kinetics. However, further kinetic studies of compound 3 with the SARS CoV-1 3CL pro protein demonstrated irreversible time-dependent inactivation of this enzyme (k obs /I = 5834 ± 151 M −1 s −1 ). Additionally, 3 possessed potent antiviral activity in Vero cells (EC 50 = 2.4 μM) and solubility in vehicle formulations almost 20-fold higher than 22. Evaluation of the pharmacokinetic profile of 3 in rat suggested that this inhibitor possessed properties potentially sufficient for an IV continuous infusion dosing paradigm. 42 Although irreversible inhibition can provide an extended pharmacodynamic effect when protein resynthesis rate is slow compared to drug clearance, such extended effects for 3CL pro inhibition were not necessarily expected. The 3CL pro -mediated proteolysis of newly expressed viral polyproteins is essential to virus replication; however, this activity only occurs during a single step in the virus life cycle that closely follows each cell infection. Viral particles themselves are not reliant on 3CL pro activity nor are the remaining coronavirus life cycle steps. Each event of cell infection initiates newly synthesized 3CL pro . Because detailed kinetics of this process are not understood, reversible and irreversible inhibitors were investigated equally.

Reversible Inhibitors of SARS CoV-1 3CL pro . Peptidyl HMK inhibitors and their corresponding ethers have been designed as potent reversible cysteine protease inhibitors of cathepsin 43 High-resolution crystal structures of two such inhibitors complexed with cruzain highlighted the presence of a strong hydrogen bond between the catalytic His and the α-hydroxyl moiety of the inhibitor but interestingly no covalent bond between the active-site Cys and the ketone pharmacophore. Utilizing the crystal structure of 28 in complex with SARS CoV-1 3CL pro , molecular modeling of an HMK-based design indicated the potential for establishing a covalent bond between the sulfur of the active-site cysteine (Cys145) and the HMK carbonyl as well as hydrogen bond interactions between catalytic His41 and the terminal hydroxy moiety. Additionally, the structure of 28 suggested the possibility to increase the lipophilic filling of the deep hydrophobic S 2 pocket as a strategy to increase binding affinity. To evaluate these structure-based observations, a series of reversible HMK inhibitors containing P 2 diversity were prepared as depicted in Table 3 .

As suggested by molecular modeling, the S 2 site appears to accommodate a variety of linear, branched, and cyclic alkyl moieties (entries 36 and 39−41). Interestingly, the P 2 Phe derivative 42 displayed less potent inhibition of the SARS CoV-1 3CL pro than the corresponding saturated analogue 41. Also noteworthy is the large attenuation in enzyme inhibition seen with P 2 -N-methyl-Leu inhibitor 38 (IC 50 = 83 nM) as compared to 4 (K i = 4 nM). This loss of potency is consistent with the inhibitor ligand interactions observed with 2 and 4 that show the P 2 NH involved in a hydrogen bond with the side-chain amide of Gln189. Additionally, the methyl substitution in 38 would be expected to alter the conformation of the 4-methoxy indole cap and perturb the observed ligand− enzyme hydrogen bond network present in 2 and 4.

The results for 4 and the other examples in Table 3 reveal a high antiviral EC 50 /enzyme IC 50 ratio, which may arise from poor cell permeability. Indeed, these HMK inhibitors exhibit very low permeability and high levels of efflux beyond the sensitivity of the Caco-2 in vitro assay. However, the impact of high efflux on antiviral potencies from Vero 76 cells (derived from monkey kidney) versus disease-relevant human lung epithelial cells is unknown. To better understand the observed high antiviral EC 50 /enzyme IC 50 ratio for 4, we evaluated the role of efflux in the Vero 76 cell line by the in vitro experimental design discussed further below. Concurrently, a strategy to design molecules reducing efflux by active transporters, such as P-glycoprotein, was pursued to decrease high antiviral EC 50 /enzyme IC 50 ratios. An analysis of the physicochemical properties of 4 suggested that increasing logP, reducing polar surface area (PSA), and reducing the number of hydrogen bond donors/acceptors were design strategies with the potential to improve cellular permeability and reduce efflux.

An examination of the crystal structure of 2 in complex with SARS CoV-1 3CL pro suggested a limited functional role for the 4-methoxy substituent contained in the P 3 indole cap. Additionally, the terminal α-hydroxyl moiety located at P 1 ′ appeared to provide a potential opportunity to remove a hydrogen bond donor. Although it was anticipated that the α- hydroxyl moiety would form a hydrogen bond to the catalytic His41, the directionality of this interaction was uncertain. As noted earlier, His41 presents a hydrogen bond donor to the interior of the protease, leaving an acceptor to participate in the proton transfer cycling from neutral to cationic in the putative catalytic mechanism 44 of proteolysis. If His41 is protonated in the inhibitor-bound complex, a lone pair from the α-hydroxyl moiety would function as a hydrogen bond acceptor from the proton on the His residue. On the other hand, if His41 is deprotonated, the hydrogen of the α-hydroxyl moiety would act as a hydrogen bond donor to the nitrogen lone pair of the His residue. Consistent with the strategy to decrease PSA and hydrogen bond donors, a series of inhibitors were prepared that contained alterations to the P 3 cap and substitution of the α-hydroxyl group. Table 4 summarizes this effort where two of the optimal P 2 residues (Leu and β-tert-butyl-Ala) were conserved. Removal of the methoxy group from the indole generally led to slightly weaker potency in both the enzymatic and antiviral assays across pairs (43 vs 36, 44 vs 37, 50 vs 48 and 49 vs 4) and therefore no improvement in the antiviral/protease inhibition ratio. The impact of more significant changes to the P 3 cap is illustrated by tetrahydrofuranyl derivatives 46 and 47. These derivatives lack the lipophilic aryl ring and NH hydrogen bond donor present in the indole P 3 cap and exhibit a pronounced reduction in enzymatic and antiviral potency. A noteworthy reduction in biochemical and antiviral potency was observed in comparing each hydroxymethylketone derivative with its corresponding ether counterpart. These results suggest that modest structural and physicochemical alterations of 4 fail to significantly decrease the high EC 50 /IC 50 ratios for this class of peptidomimetics. However, in vitro analysis of 4 revealed this derivative to possess high levels of metabolic stability in human liver microsomes (t 1/2 = 107 min). 45 Further evaluation of this breakthrough derivative in several aqueous-based formulations suitable for IV administration indicated high levels of solubility. 46 Cocrystal structures of 4 bound to the 3CL pro of both SARS CoV-1 and CoV-2 were solved at 1.47 and 1.26 Å resolutions, respectively (PDB codes 6XHL and 6XHM). 47 As expected, the ligand binding sites of the main protease from SARS CoV-1 and SARS CoV-2 are conserved in sequence and are nearly identical structurally. The schematic diagram in Figure 5 is representative of the covalent adduct between 4 and the 3CL pro from both CoV-1 and CoV-2. The warhead HMK carbonyl carbon of 4 forms a covalent bond to the 3CL pro active-site cysteine (Cys145) sulfur generating a tetrahedral carbinol complex (1.8 Å C−S bond length). This carbinol hydroxyl forms hydrogen bonds with the backbone NH of Cys145 and with the amide NH of Gly143 via a bridging water molecule. Another key active-site interaction is the hydrogen bond between the primary alcohol moiety of 4 and the catalytic His41. Similar interactions between catalytic His residues and the OH moiety of HMK in other protease−inhibitor complexes have been reported. 43 In S 1 , the lactam carbonyl of 4 forms a strong hydrogen bond with the side chain of His163, while the lactam NH is within the hydrogen-bonding distance but poorly aligned with the side-chain oxygen of Glu166 and the backbone oxygen of Phe140. These three residues partially define the bottom and edge of the S 1 pocket. Additionally, the backbone carbonyl and NH of Glu166 form β-sheet-like hydrogen-bonding interactions with the NH and C2-carbonyl of the indole fragment of 4. The NH of the P 2 Leu of inhibitor 4 and the side chain of Gln189 form a hydrogen bond, while the carbonyl of P 2 Leu is exposed to the solvent. The inhibitor P 1 NH forms a strong hydrogen bond with the backbone carbonyl of His164. The inhibitor's lipophilic leucine residue is bound to the SARS 3CL pro in the hydrophobic S 2 pocket formed by residues Asp187, Arg188, Gln189, Met49, and His41. The indole portion of 4 does not protrude into the S 3 pocket but rather rests across a partially collapsed S 3 , making extended van der Waals interactions across the 189−191 residue backbone atoms. The closed S 3 is the only significant conformational difference compared to a recently reported structure of SARS CoV-2 3CL pro inhibited by α-ketoamides. 8 The energetics of this extended interaction, the associated protein conformation stabilities, or warhead difference may contribute to the 3-orderof-magnitude increased SARS CoV-2 3CL pro potency of HMK 4 (see below) compared to that of the referenced ketoamides.

Hydroxymethylketone 4 was evaluated against a panel of other viral and human proteases (Table 5 ). In general, 4 is highly selective for 3CL pro inhibition, displaying IC 50 values of >10 μM against many of the other proteases and possessing modest levels of inhibition of cathepsin B (IC 50 = 1.3 μM) and rhinovirus 3C pro (IC 50 = 1.7 μM). High levels of similarity between the catalytic sites of 3CL pro proteases suggest the potential of 4 as a pan-coronavirus inhibitor. Testing revealed that 4 demonstrates potent inhibition of the related hCoV 229E protease (IC 50 = 0.004 μM) but more importantly, given the current global pandemic, potently inhibits SARS CoV-2 3CL pro with a K i of 0.27 nM.

The antiviral specificity of 4 was evaluated against a panel of viruses (Table 6 ). No antiviral activity was observed when 4 was tested against two human rhinovirus strains (HRV-14 and HRV-16), human immunodeficiency virus-1 (HIV-1), or human cytomegalovirus (HCMV) in cell culture. This compound also does not inhibit the HCV replicon. As anticipated by the potent hCoV 229E protease activity, 4 is a potent inhibitor of the human coronavirus hCoV 229E in MRC-5 cells (human lung-derived) with an EC 50 of 0.090 μM.

The hCoV 229E antiviral potency is more than 50-fold greater than that for SARS CoV-1 in the Vero 76 line, even though 4 possesses nearly equivalent 3CL pro biochemical potency for the hCoV 229E and CoV-1 viruses. While undefined differences between hCoV 229E and SARS CoV-1 could account for these large differences in antiviral EC 50 / enzyme IC 50 ratios, different active transporter expression levels between MRC-5 and Vero 76 cell lines may also be a contributing factor. Consistent with the previously stated goal to characterize the impact of efflux on potency measured in the SARS CoV-1 antiviral assay, we co-dosed a known Pglycoprotein transport inhibitor at a fixed concentration (0.5 μM CP-100356) 48 in a full dose−response of inhibitor 4. This resulted in a pronounced potency shift of SARS CoV-1 antiviral activity (EC 50 = 0.11 μM) that now more closely matched the antiviral potency seen for hCoV 229E. As a control, the same co-dosing of efflux inhibitor led to no such shift in the hCoV 229E antiviral potency of 4, demonstrating that the human lung-derived MRC-5 cells show less Pglycoprotein-based transporter under similar assay conditions. These results suggest that the high antiviral EC 50 /enzyme IC 50 ratio observed in Vero 76 cells is an artifact of the high efflux potential of that assay cell line and may underestimate the antiviral potency in human lung cells, the relevant tissue for SARS and COVID-19. Assays to directly measure the antiviral potency of 4 against SARS CoV-2 in clinically relevant human lung cells are currently under investigation.

This report details the efforts to identify irreversible and reversible peptidomimetic inhibitors of the SARS CoV-1 3CL pro as potential IV agents for the treatment of SARS and other coronavirus diseases. Two classes, acyloxymethylketones and hydroxymethylketones, were discovered as potent inhibitors of the SARS 3CL pro . The hydroxymethylketone derivative 4 demonstrated potent SARS CoV-1 inhibition in 3CL pro and antiviral assays. Additionally, 4 possesses acceptable solubility, stability in plasma, and low in vitro and in vivo clearances suitable for further development as a coronavirus treatment. 49 Importantly, the potent inhibition of SARS CoV-2 3CL pro has prompted further preclinical investigations of 4 as a potential therapeutic treatment for patients with COVID-19.

General Procedures. Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. The removal of solvent under reduced pressure or concentration refers to distillation using a Buchi rotary evaporator attached to a vacuum pump (3 mmHg). Products obtained as solids or high-boiling oils were dried under vacuum (1 mmHg). Silica gel chromatography was performed on either a CombiFlash (Teledyne ISCO), SP4, or Isolera (Biotage) purification system. All reactions were performed under a positive pressure of nitrogen or argon or with a drying tube at an ambient temperature (unless otherwise stated) in anhydrous solvents, unless otherwise indicated. Analytical thin-layer chromatography (TLC) was performed on glass-backed silica gel 60 F254 plates (Analtech, 0.25 mm), eluting with the appropriate solvent ratio (v/v). The reactions were assayed by high-performance liquid chromatography−mass spectrometry (LCMS) or TLC and terminated as judged by the consumption of the starting material. LCMS utilized wavelengths of 254 and 220 nm and either electrospray ionization (ESI) in positive mode or atmospheric-pressure chemical ionization (APCI) in positive mode. The TLC plates were visualized using UV light, p-anisaldehyde, phosphomolybdic acid, or iodine staining. Microwave-assisted reactions were run in a Biotage Initiator. 1 H NMR spectra were recorded on a Bruker XWIN-NMR (400 MHz) spectrometer. Proton chemical shifts are reported in parts per million downfield from tetramethylsilane (TMS). 1 H NMR data are reported as chemical shift (multiplicity, coupling constant, integration). Multiplicities are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; and brs, broad singlet. For spectra obtained in CDCl 3 , DMSO-d 6 , and CD 3 OD, the residual protons (7.27, 2.50, and 3.31 ppm, respectively) were used as the internal references. The purity of the final products is >95% as determined by HPLC and/or 1 H NMR analyses.

N-(tert-Butoxycarbonyl)-3-[(3S)-2-oxopyrrolidin-3-yl]-L-alanine (6). A 3 L multineck flask equipped with an overhead stirrer and internal thermometer was charged with methyl N-(tert-butoxycarbonyl)-3-[(3S)-2-oxopyrrolidin-3-yl]-L-alaninate (compound 5) 33 (205 g, 716 mmol) followed by methanol (1 L), and the solution was cooled to 0°C using ice/NaCl bath. NaOH (115 g in 950 mL water, 2.9 mol) solution was precooled to 0°C and then added to the flask via a pressure-equalizing dropping funnel at such a rate to maintain the internal temperature below 5°C. The resulting solution was stirred at 0°C for 1 h before neutralizing with conc. hydrochloric acid (keeping the internal temperature below 10°C) and then removing the methanol in vacuo. The residue was diluted with ethyl acetate (400 mL), acidified to pH 3 with conc. hydrochloric acid, and then the mixture was transferred to a sep funnel, and the organics were removed. The aqueous was extracted with ethyl acetate (2 × 400 mL), and the combined organics were washed with brine, dried over MgSO 4 , filtered, and concentrated to yield the title compound as a white foam, 95%. 1 10 .0 mmol) in THF (100 mL) was placed under an atmosphere of N 2 and cooled to −23°C. The resulting clear colorless solution was successively treated with triethylamine (2.1 mL, 15.0 mmol) followed by isobutylchloroformate (1.6 mL, 12.0 mmol). The reaction mixture gradually became opaque with a fine white precipitate and after 1 h was filtered. The colorless filtrate was transferred to a nonground joint flask, cooled to 0°C, and slowly treated with a solution of diazomethane (∼35 mL, ∼16.6 mmol) in diethyl ether. Note: The diazomethane was generated employing a Diazald kit according to the procedure described in the Aldrich Technical Bulletin AL-180. The resulting yellow clear solution was gradually warmed to room temperature (RT) over 16 h. At this time, N 2 was bubbled through the reaction to remove excess diazomethane followed by in vacuo concentration. The resulting residue was diluted with ethyl acetate (100 mL), washed once with sat. NaHCO 3 (50 mL), once with brine (50 mL), dried over MgSO 4 , filtered, and concentrated to give a crude yellow foam. (8) . A three-neck flame-dried flask equipped with a nitrogen inlet and internal thermometer was charged with methyl N-(tert-butoxycarbonyl)-3-[(3S)-2-oxopyrrolidin-3-yl]-Lalaninate (10 g, 35 mmol), THF (200 mL), and chloroiodomethane (10.2 mL, 140 mmol), and the solution was cooled to −77°C. LDA (140 mL, 210 mmol, 1.5 M mono-THF complex in cyclohexane) was added via a pressure-equalizing dropping funnel at such a rate to keep the internal temperature below −70°C. After complete addition, the reaction was stirred for an additional hour and quenched with a mixture of AcOH (33 mL) and THF (200 mL) with a rate of addition regulated to maintain the internal temperature below −65°C. After complete addition, the dark suspension was stirred for 10 min and then warmed to an ambient temperature. The reaction was diluted with ethyl acetate (500 mL), and the organics were washed with water (250 mL), satd. NaHCO 3 (250 mL), and brine (250 mL), dried over MgSO 4 , filtered, and the solvents were removed in vacuo to yield the crude product as a dark oil, which was purified by flash chromatography eluting with ethyl acetate. The resulting solid was triturated with diethyl ether to afford the title compound as a pale yellow solid, 5.7 g, 54%. 1 tert (9) . To a 3 L multinecked flask equipped with an overhead stirrer, nitrogen inlet, and internal thermometer was charged N-(tert-butoxycarbonyl)-3-[(3S)-2-oxopyrrolidin-3-yl]-L-alanine (190 g, 698 mmol) followed by dichloromethane (1100 mL) and the solution was cooled to 0°C employing an ice/NaCl bath. N,O-Dimethylhydroxylamine hydrochloric acid salt (68 g, 698 mmol) was added followed by N-methylmorpholine (230 mL, 2.09 mol), HOBt.hydrate (106 g, 698 mmol), and EDCI (147 g, 768 mmol), and the mixture was stirred at 0°C under nitrogen for 6 h before quenching with water (500 mL). The biphasic mixture was transferred to a sep funnel, and the organics were isolated, washed with 1 M hydrochloric acid (2 × 500 mL), water (400 mL), satd. NaHCO 3 (2 × 700 mL), and brine (300 mL) and then dried over To a 100 mL multinecked flask equipped with a stirrer bar, nitrogen inlet, and internal thermometer were charged magnesium turnings (dried in oven at 100°C overnight, 1.04 g, 43 mmol) and HgCl 2 (774 mg, 2.85 mmol), and the flask was purged with nitrogen for 10 min. THF (50 mL) was added, and the suspension was cooled to −45°C before adding BOM-Cl (5.94 mL, 43 mmol), and the resulting suspension was stirred for 5 h, the temperature returning to 5°C. The suspension was recooled to −50°C, and tert-butyl ((1S)-2-[methoxy(methyl)amino]-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}ethyl)carbamate (1.5 g, 4.76 mmol) was added, and the thick suspension was stirred for 48 h under nitrogen and was allowed to come to an ambient temperature. The reaction was quenched by the careful addition of satd. NH 4 Cl solution (25 mL), and the mixture was stirred until effervescence ceased and then extracted with ethyl acetate (3 × 120 mL). The combined organics were dried over MgSO 4 , filtered, and the solvents were evaporated in vacuo to yield a crude orange gum, which was purified by flash chromatography, eluting with 1−3% methanol/dichloromethane to afford the title compound as a clear glass, 900 mg, 50%. 1 tert A solution of the crude hydrochloride salt and 4-methoxy-1Hindole-2-carboxylic acid (123 mg, 0.64 mmol) in DMF (2.5 mL) was placed under an atmosphere of N 2 and cooled to 0°C. This pale yellow solution was successively treated with HATU (245 mg, 0.64 mmol) and N-methylmorpholine (0.14 mL, 1.29 mmol) turning a brighter color. After 30 min, the reaction was quenched with 1:1 ice/ sat NaHCO 3 (25 mL) and extracted three times with ethyl acetate (20 mL). The combined organics were washed once with brine (30 mL), dried over MgSO 4 , filtered, and concentrated to give a yellow syrup. This material was purified by LC (30 g 230−400 SiO 2 , 4% methanol/chloroform) to afford 167 mg (58%) of the title compound as an off-white solid ( (25) . Following the procedure described for the preparation of (3S)-3- Methyl N-(tert-Butoxycarbonyl)-5-methyl-L-norleucinate. To a solution of methyl N-[(9H-fluoren-9-ylmethoxy)carbonyl]-5-methyl-L-norleucinate (2.18 g, 5.72 mmol) in DMF (50 mL) was added KF (2.33 g, 40.04 mmol) followed by triethylamine (1.70 mL, 12.24 mmol) and di-tert-butyl dicarbonate (7.39 mmol), and the mixture was stirred at an ambient temperature. After 4 h, TLC analysis indicated incomplete reaction and the reaction mixture was treated with a second portion of KF (2.7 g, 46.55 mmol) and BOC 2 O (800 mg, 3.67 mmol). After 16 h, the mixture was diluted with diethyl ether (300 mL), washed with satd. NaHCO 3 (2 × 50 mL), 1 M hydrochloric acid (2 × 50 mL), NaHCO 3 (50 mL), and brine (50 mL), dried over MgSO 4 , filtered, and the solvents were evaporated in vacuo to yield the crude product, which was purified by Biotage flash chromatography eluting with dichloromethane/hexane to afford the title compound as a clear oil, 980 mg, 66% N-(tert-Butoxycarbonyl)-5-methyl-L-norleucine. To a solution of methyl N-(tert-butoxycarbonyl)-5-methyl-L-norleucinate (980 mg, 3.78 mmol) in THF (30 mL) at 0°C was added a solution (precooled to 5°C) of LiOH (1 M, 11.3 mL, 11.33 mmol), and the resulting mixture was stirred at 0°C for 1 h and then allowed to warm to an ambient temperature. The reaction was acidified to pH 2 with 1 M hydrochloric acid and extracted with ethyl acetate (3 × 60 mL). , and the solution was stirred at an ambient temperature for 4 h before removing the solvents in vacuo, azeotroping the residue with toluene (2 × 10 mL), and drying in vacuo for 1 h. The crude hydrochloride salt was taken into DMF (3 mL), and the solution was cooled to 0°C before adding N-Boc-cyclohexylalanine-OH (139 mg, 0.53 mmol), collidine (156 μL, 1.22 mmol), and HATU (194 mg, 0.53 mmol) in order, and the resulting suspension was stirred at 0°C for 5 h. The reaction was quenched by the addition of water (30 mL), and the mixture was extracted with diethyl ether (3 × 75 mL). The combined organics were dried over MgSO 4 , filtered, and the solvents were removed in vacuo to yield the crude product, which was purified by flash chromatography, eluting with 1−3% methanol/dichloromethane to afford the title compound as a pale brown gum, 205 mg, methanol, sample loaded in chloroform) resulting in the isolation of 1. 13 where offset equals the fluorescence signal of the uncleaved peptide substrate, and limit equals the fluorescence of the fully cleaved peptide substrate. The k obs is the first-order rate constant for this reaction and, in the absence of any inhibitor, represents the utilization of a substrate. In an enzyme start reaction, which contains an irreversible inhibitor, and where the calculated limit is less than 20% of the theoretical maximum limit, the calculated k obs represents the rate of inactivation of coronavirus 3CL protease. The slope (k obs /I) of a plot of k obs vs [I] is a measure of the avidity of the inhibitor for an enzyme. For very fast irreversible inhibitors, k obs /I is calculated from observations at only one or two [I] rather than as a slope. For the determination of IC 50 values for reversible inhibitors, the data was analyzed with the nonlinear regression analysis programs Xlfit3.05 (IDBS, Guildford, U.K.) or GraphPad Prism 8.02 (GraphPad Software San Diego, CA). SARS CoV-2 Protease FRET Assay and Analysis. The proteolytic activity of the main protease, 3CL pro , of SARS CoV-2 was monitored using a continuous fluorescence resonance energytransfer (FRET) assay. The SARS CoV-2 3CL pro assay measures the activity of full-length SARS CoV-2 3CL protease to cleave a synthetic fluorogenic substrate peptide with the following sequence DABCYL-KTSAVLQ-SGFRKME-EDANS modeled on a consensus peptide. 50 The fluorescence of the cleaved EDANS peptide (excitation 340 nm/ emission 490 nm) is measured using a fluorescence intensity protocol on a Flexstation reader (Molecular Devices). The fluorescent signal is reduced in the presence of PF-00835231, a potent inhibitor of SARS CoV-2 3CL pro . The assay reaction buffer contained 20 mM Tris−HCl (pH 7.3), 100 nM NaCl, 1 mM EDTA, 5 mM TCEP, and 25 μM peptide substrate. Enzyme reactions were initiated with the addition of 15 nM SARS CoV-2 3CL protease and allowed to proceed for 60 min at 23°C. Percent inhibition or activity was calculated based on control wells containing no compound (0% inhibition/100% activity) and a control compound (100% inhibition/0% activity). IC 50 values were generated using a four-parameter fit model using ABASE software (IDBS). K i values were fit to the Morrison equation with the enzyme concentration parameter fixed to 15 nM, the K m parameter fixed to 14 μM, and the substrate concentration parameter fixed to 25 μM using Activity Base software (IDBS).

SARS CoV-1 Antiviral Assays. All assays were performed in BSL3 containment. Vero 76 cells were plated at 10 000 cells per well using phenol red-free DMEM or IMEM (Gibco). After adhering for 2 h at 37°C, various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added and the cells were infected with 2.6 × 10 3 PFU/well SARS CoV Toronto-2 (provided as a gift from Dr. Heinz Feldman (NIAID, Hamilton, MT)) or mock-infected with the medium only. After 66 h, cell viability was determined using either the neutral red method or the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). For the neutral red method, the cells were washed twice with PBS, and 100 μL of DMEM pH 4.5 containing 0.066% neutral red was added to the cells for 2 h at 37°C. The cells were again washed twice with PBS, 100 μL of buffer solution (50% EtOH, 1% acetic acid) was added, and the OD was read at 540 nM after a 10 min incubation at 37°C with shaking. Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC 50 ) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC 50 ) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells. 51, 52 hCOV 229E Antiviral assays. MRC-5 cells were plated at 10 000 cells per well using phenol red-free MEM (Gibco). Various concentrations of compound (320, 100, 33, 10, 3.3, 1.0, 0.3, or 0.1 μM) were added, and the cells were infected with an amount of hCoV 229E, which caused 80% cell death in 4 days or mock-infected with the medium only. After 4 days, cell viability was determined using the XTT dye reduction method. 53 Data are expressed as the percent of neutral red or luminescent signal in wells of compound-treated cells compared to the signal in wells of uninfected, compound-free cells. The 50% effective concentration (EC 50 ) is calculated as the concentration of the compound that increases the percent of the neutral red or luminescent signal in infected, compound-treated cells to 50% of that produced by uninfected, compound-free cells. The 50% cytotoxicity concentration (CC 50 ) is calculated as the concentration of the compound that decreases the percent of the neutral red or luminescent signal in uninfected, compound-treated cells to 50% of that produced in uninfected, compound-free cells.

Other Antiviral Assays. The following antiviral assays for HCMV, 54 HIV-RF, 55 HRV-14, and HRV-16, 54 as well as the HCV replicon, 56,57 were performed as described in the above references.

Expression and Purification of CoV-2 3CL Protease. The expression and purification strategy followed previous studies on SARS CoV-1 3CL pro . 58 Genes encoding SARS CoV-1 3CL pro and SARS CoV-2 M pro MN908947.3 were synthesized with codon usage optimized for Escherichia coli expression (Genscript and IDT). Genes were cloned into a modified pET24a vector to produce a TEVcleavable N-terminal 6xHis tag under the T7 promoter control. BL21(DE3) cells (LifeTech) were grown in Terrific Broth (Teknova) at 37°C until an OD 600 = 0.6−0.8 and induced with 0.4 M IPTG for 5 h at 30°C. Cell pellets were stored at −80°C until purification. Cell pellets were resuspended and lysed by microfluidization in Buffer A (20 mM Tris pH 8.0 + 150 mM NaCl). Lysates were clarified at 25,000 × g for 1 h at 4°C. The soluble lysate was loaded onto a nickel affinity column (Probond) and washed sequentially with Buffer A + 5 mM and 20 mM imidazole. The proteases were eluted with Buffer A + 300 mM imidazole. The His-tag was removed by TEV protease (1:40) during an overnight dialysis step in Buffer A + 1 mM DTT. The CoV M pro proteins were further purified on a HiTrap Q hp (GE Healthcare), and the Q-flow-through material was concentrated and loaded onto a 26/60 Superdex-75 (GE Healthcare) gel filtration column equilibrated with Buffer B (20 mM Tris pH 7.8 + 150 mM NaCl + 1 mM EDTA + 1 mM DTT). Final proteins were concentrated from 5 to 25 mg/mL and were directly moved to crystallization experiments or snap-frozen in liquid nitrogen for storage.

Crystallization/Soak Protocols for SARS1 with 2. Crystals of compound 2 bound to SARS1/CoV-1 DC2 protease were produced via cocrystallization. SARS1/CoV-1 DC2 protease at 10.00 mg/mL was incubated with a 3-fold molar excess of compound 2 for 18 h at 4°C

. The complex was then passed through a 0.45 μM cellulose acetate spin filter and set up for crystallization using an NT-8 crystallization robot (Formulatrix). Using MRC-2 crystallization plates, wells containing 40 μL of 4% w/v PEG 6000, 0.1 M MES pH 6.0, and 2.5 mM DTT were dispensed, and then sitting drops consisting of 0.3 μL protein were set up against a 0.3 μL well buffer. Crystallization plates were incubated at 21°C, and rectangular crystals measuring 0.1 × 0.25 × 0.25 mm 3 grew within 24 h. Cocrystals were flash-frozen in liquid nitrogen after being passed through a cryo consisting of a well buffer containing 20% glycerol.

Crystallization/Soak Protocols for SARS1 with 28. Crystals of compound 28 bound to SARS1/CoV-1 DC2 protease were produced via cocrystallization. SARS1/CoV-1 DC2 protease at 10.00 mg/mL was incubated with a 3-fold molar excess of compound 28 for 18 h at 4°C. The complex was then passed through a 0.45 μM cellulose acetate spin filter and set up for crystallization using an NT-8 crystallization robot (Formulatrix). Using MRC-2 crystallization https://pubs.acs.org/10.1021/acs.jmedchem.0c01063

The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding for the antiviral testing was provided by NIAID under a cooperative agreement between NIAID and Pfizer.

CDCl 3 ) δ 7.69 (d

Hz, 1H), 7.26−7.42 (m, 5H), 5.93 (s, 1H), 4.94 (d, J = 7.6 Hz, 1H)

mg, 0.38 mmol) in dioxane (4 mL) was added 4 M hydrochloric acid/ dioxane (4 mL), and the solution was stirred at an ambient temperature for 2 h before removing the solvents in vacuo, azeotroping the residue with toluene (2 × 10 mL), and drying in vacuo for 1 h. The crude hydrochloride salt was taken into DMF (3 mL), and the solution was cooled to 0°C before adding 4-methoxyindole-2-carboxylic acid (73 mg, 0.38 mmol), collidine (125 μL, 0.95 mmol), and HATU (144 mg, 0.38 mmol) in order, and the resulting suspension was stirred at 0°C for 6 h. The reaction was quenched by the addition of water (20 mL), and the mixture was extracted with diethyl ether (3 × 50 mL). The combined organics were washed with water (20 mL) and brine (20 mL), dried over MgSO 4 , filtered, and the solvents were removed in vacuo to yield the crude product, which was purified by Biotage flash chromatography, eluting with 1−3% methanol/dichloromethane to afford the title compound as a pale brown gum, 90 mg, 39%. The product was contaminated with ∼20% of another diastereomer from the previous step. 1 H NMR (400 MHz, CDCl 3 ) δ 9

mmol) in EtOH (3 mL) was added 10% Pd/C (50 mg), and the suspension was hydrogenated at an ambient temperature under H 2 (1 atm balloon) for 5 h. The catalyst was removed by filtration, and the solvents were evaporated in vacuo to yield the crude product

−2.03 (m, 1H), 1.53−1.79 (m, 9H), 1.31−1.45 (m, 1H)

MS (APCI+) for C 27 H 36 N 4 O 6 m/ z 513.2. (M + H) + ; anal

Following the procedure described for the preparation of N 2 -(tert-butoxycarbonyl)-N 1 -((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)-L-leucinamide but substituting Boc-Phe-OH and making noncritical variations provided a crude brown oil. This material was purified by Biotage flash chromatography, eluting with methanol/ dichloromethane to afford the title compound as a white solid, 351 mg, 36%. 1 H NMR (400 MHz

-methoxy-1H-indol-2-yl)carbonyl]-L-phenylalaninamide. Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N-(tert-butoxycarbonyl

L-phenylalaninamide and making noncritical variations provided a crude green solid. This material was purified by Biotage flash chromatography, eluting with methanol/dichloromethane to afford the title compound as a white solid, 300 mg

Hz, 1H), 8.61 (d, J = 7.8 Hz, 1H), 7.61 (s, 1H), 7.37 (d, J = 7.1 Hz, 2H), 7.31 (d, J = 1.8 Hz, 1H), 7.26 (t, J = 7.6 Hz, 2H), 7.16 (t, J = 7.2 Hz, 1H), 7.07 (t, 1H)

Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N-((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)-N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-phenylalaninamide and making noncritical variations provided a crude greenish gum. This material was purified by Biotage flash chromatography, eluting with methanol/dichloromethane to afford the title compound as an off-white solid, 123 mg, 44%. 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.50 (d, J = 2.0 Hz, 1H), 8.58 (dd

MS (APCI+) for C 27 H 30 N 4 O 6 m/z 507.1 (M + H) + ; anal. calcd for C 27 H 30 N 4 O 6 · 1.25 H 2 O: C

)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3,3-dimethylbutyl)-1H-indole-2-carboxamide. Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N 2 -(tert-butoxycarbonyl)-N 1 -((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)-4-methyl-L-leucinamide and indole-2-carboxylic acid and making no other critical variations provided a crude yellow foam

DMSO-d 6 ) δ 11.59 (s, 1H), 8.58 (d, J = 8 Hz, 1H), 8.50 (d, J = 8 Hz, 1H), 7.64 (s, 1H), 7.61 (d, J = 8 Hz, 1H)

MS (ESI+)

Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)amino]carbonyl}-3,3-dimethylbutyl)-1H-indole-2-carboxamide and making noncritical variations provided a crude yellow foam. This material was purified by Biotage MPLC (40 M column, 4.5− 5.5% methanol/chloroform) to afford 730 mg (72%) of the title compound as a white solid. 1 H NMR (DMSO-d 6 ) δ 11.59 (s, 1H), 8.49 (d, J = 8 Hz, 1H)

MS (ESI+) for C 24 H 32 N 4 O 5 m/z 457.1 (M + H) + ; anal

Following the procedure described for the preparation of 4-methoxy-N-((1S)-1-{[((1S)-3-methoxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-4-methylpentyl)-1H-indole-2-carboxamide but substituting N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)amino]carbonyl}-3,3-dimethylbutyl)-1H-indole-2-carboxamide and making noncritical variations provided a crude tan foam

Hz, 1H), 7.23 (s, 1H), 7.17 (t, J = 8 Hz, 1H)

Hz, 1H), 3.23 (s, 3H), 3.06 (m, 2H), 2.27 (m, 1H), 2.07 (m, 1H), 1.91 (m, 1H), 1.79 (m, 1H), 1.69 (m, 3H)

MS (ESI+) for C 25 H 34 N 4 O 5 m/z 471.2 (M + H) + ; anal. calcd for C 25 H 34 N 4 O 5 ·0

Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-methoxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-3,3-dimethylbutyl)-1H-indole-2-carboxamide but substituting iodoethane and making noncritical variations provided a crude tan foam. This material was purified by Biotage MPLC (25 M column, 3−5% methanol/ chloroform) to afford 19 mg (6%) of the title compound as an offwhite solid. 1 H NMR (DMSO-d 6 )

Hz, 1H), 7.23 (s, 1H), 7.17 (t, J = 8 Hz, 1H)

Hz, 1H), 3.41 (m, 2H), 3.06 (m, 2H), 2.26 (m, 1H), 2.09 (m, 1H), 1.91 (m, 1H), 1.82 (m, 1H), 1.63 (m, 3H)

MS (ESI+) for C 26 H 36 N 4 O 5 m/z 485.2 (M + H) +

3-Chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)-4-methyl-N 2 -[(2R)-tetrahydrofuran-2-ylcarbonyl]-L-leucinamide. Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N 2 -(tert-butoxycarbonyl)-N 1 -((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)-4-methyl-L-leucinamide and (2R)-tetrahydrofuran-2-carboxylic acid and making noncritical variations provided a crude product

3-Chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-1H-indole-2-carboxamide. Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]-methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting indole-2-carboxylic acid and making noncritical variations provided a crude orange foam. This material was purified by Biotage flash chromatography, eluting with methanol/dichloromethane to afford the title compound as an offwhite solid, 1.75 g, 82%. 1 H NMR (400 MHz

Following the procedure described for the preparation of N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-3-methylbutyl)-4-methoxy-1H-indole-2-carboxamide but substituting N-((1S)-1-{[((1S)-3-chloro-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)amino]carbonyl}-3-methylbutyl)-1H-indole-2-carboxamide and making noncritical variations provided a crude black gum. This material was purified by Biotage flash chromatography, eluting with methanol/dichloromethane to afford the title compound as an offwhite solid, 218 mg

Hz, 1H), 7.26 (s, 1H), 7.17 (t, J = 7.6 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 5.02 (t, 1H)

MS (APCI+) for C 23 H 30 N 4 O 5 m/z 443.1 (M + H) + ; anal. calcd for C 23 H

Following the procedure described for the preparation of 4-methoxy-N-((1S)-1-{[((1S)-3-methoxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-4-methylpentyl)-1H-indole-2-carboxamide but substituting N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}-propyl)amino]carbonyl}-3-methylbutyl)-1H-indole-2-carboxamide and making noncritical variations provided a crude pale brown oil. This material was purified by Biotage flash chromatography

Hz, 1H), 7.62 (d, J = 8.1 Hz, 1H)

−7.29 (m, 1H), 7.11 (t, J = 7.5 Hz, 1H), 6.98 (dd, J = 11

Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H), 5.98 (d, J = 13.1 Hz, 1H

Proteolytic activity of coronavirus 3CL protease is measured using a continuous fluorescence resonance energy-transfer assay. The SARS 3CL pro FRET assay measures the protease-catalyzed cleavage of TAMRA-SITSAVLQSGFRKMK-(DABCYL)-OH to TAMRA-SITSAVLQ and SGFRKMK(DABCYL)-OH. The fluorescence of the cleaved TAMRA (ex. 558 nm/em. 581 nm) peptide was measured using a TECAN SAFIRE fluorescence plate reader over the course of 10 min. plates, wells containing 40 μL of 10% w/v PEG 8000, 0.2 M sodium chloride, 0.1 M sodium potassium phosphate pH 6.2, and 10 mM TCEP were dispensed

Crystals of PF-00835231 bound to SARS1/CoV-1 DC2 protease via cocrystallization: Freshly prepared SARS1/CoV-1 DC2 protease at 10.00 mg/mL was incubated with a 3-fold molar excess of PF-00835231 for 18 h at 4°C. The complex was then passed through a 0.45 μM cellulose acetate spin filter and set up for crystallization using an NT-8 crystallization robot (Formulatrix)

Crystals of PF-00835231 bound to SARS2/CoV-2 mature protease via cocrystallization: Freshly prepared SARS2/CoV-2 mature protease at 11.3 mg/mL was incubated with a 3-fold molar excess of PF-00835231 for 18 h at 4°C. The complex was then passed through a 0.45 μM cellulose acetate spin filter and set up for crystallization using an NT-8 crystallization robot (Formulatrix). Using MRC-2 crystallization plates

Using MRC-2 crystallization . PF-00835231 (in 100% DMSO solution) was introduced to the drop (in situ), at a final concentration of 1 mM, and then incubated at 13°C for 24 h. Soaked crystals were flash-frozen in liquid nitrogen after being passed through a cryo consisting of a well buffer containing 20% glycerol. Structure determination. X-ray diffraction data were collected at the IMCA-CAT 17-ID beamline of Advanced Photon Source at Argonne National Labs and processed using autoPROC. Structure of the SARS CoV main protease in complex with PF-835231 was determined by molecular replacement using the published protein structure (PDBID 1Q2W) as the starting model in program Phaser and refined iteratively using autoBUSTER followed by model building in Coot. Structure of the SARS CoV-2 main protease in complex with PF

United States Ketan S. Gajiwala − Pfizer Worldwide Research and Development

United States Michelle T. Marra − Pfizer Worldwide Research and Development

United States Simon P. Planken − Pfizer Worldwide Research and Development

United States James E. Solowiej − Pfizer Worldwide Research and Development

The genome sequence of the SARSassociated coronavirus

Cumulative Number of Reported Probable Cases

Mechanisms and enzymes involved in SARS coronavirus genome expression

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements

Small peptidic aldehyde inhibitors of human rhinovirus 3C protease

Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease

Peptide aldehyde inhibitors of hepatitis A virus 3C proteinase

Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K

General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain

Reversible covalent inhibition of papain by a peptide nitrile. Carbon-13 NMR evidence for a thioimidate ester adduct

N-substituted peptidyl nitriles as cysteine cathepsin inhibitors. WO01/87828 A1, publication date

Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases

Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors

Cysteine proteases and their inhibitors

Structure and stereochemistry of tetrahedral inhibitor complexes of papain by direct NMR observation

Hilgenfeld, R. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment

New inhibitors of cysteine proteinases. Peptidyl acyloxymethyl ketones and the quiescent nucleofuge strategy

P1 aspartate-based peptide alpha-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent timedependent inhibitors of interleukin-1 beta-converting enzyme

A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones

1763−1767. (29) The X-ray crystallographic coordinates for the SARS CoV-1 3CL pro covalently bound with inhibitor 2 is deposited in the Protein Data Bank

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements

Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L

An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester

Generation of diazomethane followed Aldrich technical bulletin AL-180 employing Diazald kit

Novel route to the synthesis of peptides containing 2-amino-1′-hydroxymethyl ketones and their application as cathepsin K inhibitors

These conditions result in detectable levels of epimerization at the P 1 site. The resulting diastereomer has been observed by HPLC, NMR, and LCMS and is readily removed by fractional recrystallization

Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases

The X-ray crystallographic coordinates for the SARS CoV-1 and SARS CoV-2 3CL pro each covalently bound inhibitor 28 are deposited in the Protein Data Bank

Compound is incubated at 1 μM substrate concentration and 5 mM GSH in pH 7.8 0.1 M TRIS buffer at 37°C. Timepoints are taken over 30 min and terminated with 250 mM iodoacetamide to quench the excess GSH. Samples were then diluted in acetonitrile for LC/MS analysis. Data are reported as half-life. (41) Compound is spiked at 1 μM substrate concentration in pH 7.4 adjusted (with HCL or NaOH) plasma and incubated at 37°C. 50 μL LC/MS. Data are reported as half-life. (42) The solubility of 3 is 0.377 mg/mL (2.5% w/v SBECD, 5 mM phosphate buffer

EtOH/40% saline formulation. For 2 mg/kg dose the following values were obtained: 26.2 mL/min/kg CL

Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain

The protein structures that shape caspase activity, specificity, activation and inhibition

Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes

The X-ray crystallographic coordinates for the SARS CoV-1 3CL pro (PDB Code 6XHL) and SARS CoV-2 3CL pro (6XHM) each covalently bound inhibitor 4 are deposited in the Protein Data Bank

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999, 59, 3944−3948. (49) In vivo parameters for 4 were from IV dosing using a 50% PEG 200/10% EtOH/40% saline formulation

For dog (2 mg/kg) the following values were obtained: 10.5 mL/min/kg CL; 0.4 L/kg Vdss; 1.3 t 1/2 ; and 3.8 h·μg/mL AUC. For monkey (4 mg/kg) the following values were obtained: 20.6 mL/min/kg CL

Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery

Toxicity determined in vitro by morphological alterations and neutral red absorption

Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines

New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity

A rapid assay for determination of antiviral activity against human cytomegalovirus

In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease

Efficient initiation of HCV RNA replication in cell culture

Steady-state and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL pro cysteine protease: development of an ion-pair model for catalysis

The authors declare no competing financial interest.

The authors would like to thank the Pfizer La Jolla Discovery Technology group who were responsible for all HRMS, preparative HPLC, and SFC separations. Antiviral testing was performed at the Southern Research Institute (Birmingham, AL). The authors wish to thank Dr. Heinz Feldman (NIAID, Hamilton, MT) for the kind gift of the SARS CoV Toronto-2 cell line enabling this testing. The authors wish to thank Cathy Laughlin, Christopher Tseng, and Jack Secrist for their roles in this collaboration. The authors would also like to thank Kevin Freeman-Cook, Charlotte Allerton, and Gina M. Yanochko-Hoffman for critically reading the manuscript and offering valued editing suggestions.

Complete contact information is available at: